Warrants of series TO 4 were subscribed to approximately 92.6 percent and Smoltek Nanotech Holding AB (publ) receives approximately SEK 22.0 million
This press release is an English version of the previously published Swedish version, which has interpretive precedence.
Smoltek Nanotech Holding AB (publ) (”Smoltek” or the ”Company”) announces today the outcome of the exercise of warrants of series TO 4, which were issued during the fourth quarter of 2020. In total, 1,168,078 warrants of series TO 4 were exercised, corresponding to approximately 92.6 percent of the total number of outstanding warrants of series TO 4, for subscription of 1,168,078 shares at a subscription price of SEK 18.82 per share. Smoltek will receive approximately SEK 22.0 million before issue costs through the exercise of the warrants of series TO 4.
Background
The subscription period for exercise of the warrants of series TO 4 took place from October 20, 2021 up to and including November 3, 2021. The subscription price per share for exercising the warrants of series TO 4 was set to SEK 18.82.
In total, 1,168,078 warrants of series TO 4 were exercised for subscription of 1,168,078 shares, meaning that approximately 92.6 percent of all outstanding warrants of series TO 4 were exercised for subscription of shares.
Exercised warrants have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted to shares within approximately three (3) weeks.
Number of shares, share capital and dilution
Through the exercise of the warrants of series TO 4, the number of shares in Smoltek increases by 1,168,078 shares, from 8,114,817 shares to a total of 9,282,895 shares. The share capital will increase by approximately SEK 139,151.31, from approximately SEK 966,705.50 to approximately SEK 1,105,856.81.
For existing shareholders who did not exercise any warrants of series TO 4, the dilution amounts to approximately 12.6 percent based on the number of shares following exercise of the warrants of series TO 4.
Advisers
Mangold Fondkommission AB is financial adviser and issuing agent and MAQS Advokatbyrå AB is legal advisor to Smoltek in connection with the exercise of the warrants of series TO 4.
For questions regarding the warrants, please contact:
Mangold Fondkommission AB
Tel: +46 8 5050 1595
Email: emissioner@mangold.se
For additional information:
Håkan Persson, CEO of Smoltek Nanotech Holding AB,
E-mail: hakan.persson@smoltek.com
Phone: +46 760 52 00 53
Website: www.smoltek.com/investors
This disclosure contains information that Smoltek Nanotech Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 05-11-2021 09:06 CET.
Smoltek develops process technology and concepts for applications based on carbon nanotechnology to solve advanced materials engineering problems in several industrial sectors. The company protects its unique technology through an extensive and expanding patent portfolio consisting of around 100 applied for patents, of which today 69 have been granted. Smoltek's share is listed on the Spotlight Stock Market in Stockholm, Sweden under the ticker SMOL. Smoltek is a development company, and forward-looking statements regarding time to market, production volume and price levels should be interpreted as forecasts and not commitments.